Currently, there are no vaccines available for Respiratory Syncytial Virus (RSV), and treatment options are limited. Improvements in neutralization assays, in terms of standardization and throughput potential, for RSV would facilitate the development of novel vaccines and therapeutics. This contract supports the development of high throughput quantitative PCR assays to detect neutralizing antibody to human respiratory syncytial viruses (subtypes A and B).

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code